cd44 deletion suppresses atypia in the precancerous mouse testis

Area of Science:

• Reproductive biology
• Cancer research
• Molecular genetics

Background:

• RHAMM (Receptor for Hyaluronan-Mediated Motility) loss-of-function in mice leads to testicular atrophy, germ cell neoplasia in situ (GCNIS), and seminoma development.
• RHAMM downregulation is prevalent in human seminomas, suggesting its link to male hypofertility and GCNIS-related testicular germ cell tumors (TGCTs).
• Premature displacement of undifferentiated progenitors from the basal compartment initiates these pathologies in RHAMM-mutant testes.

Purpose of the Study:

• To investigate the role of CD44, a marker for cancer-initiating cells and oncogenic progression, in driving GCNIS development.
• To determine if CD44 exacerbates GCNIS induced by RHAMM loss-of-function in a mouse model.

Main Methods:

• Utilized a mouse model with RHAMM loss-of-function.
• Assessed CD44 expression in GCNIS testes.
• Performed genetic deletion of CD44 to evaluate its effect on GCNIS onset and oncogenic progression.

Main Results:

• CD44 expression was observed in a specific subset of GCNIS testes.
• Genetic deletion of CD44 did not affect the onset of GCNIS.
• CD44 deletion ameliorated the oncogenic progression of GCNIS.

Conclusions:

• RHAMM dysfunction is a key factor in male hypofertility and the development of GCNIS-related TGCTs.
• CD44 expression, in conjunction with RHAMM dysfunction, promotes oncogenic progression in the testis.
• CD44 is implicated in the progression of testicular germ cell tumors rather than their initiation.